slc39a14 Antibody

What is SLC39A14 and what biological functions does it serve?

SLC39A14, also known as ZIP14, is a member of the solute carrier family 39 (SLC39) of divalent metal ion transporters. It functions primarily as a multipass plasma membrane glycoprotein that mediates the cellular uptake of various metal ions. ZIP14 plays significant roles in zinc transport, which is essential for cellular growth, development, and differentiation processes . Beyond zinc homeostasis, SLC39A14 has been established as a crucial transporter of non-transferrin-bound iron (NTBI) and transferrin-bound iron, particularly in hepatocytes . Functionally, it contributes to hypozincemia during inflammation and infection, with its expression regulated in the liver by interleukin-6 (IL-6) .

The biological significance of SLC39A14 extends to iron metabolism disorders, as demonstrated by studies in hemochromatotic mice. SLC39A14 deficiency substantially reduces hepatic iron loading and prevents iron deposition in hepatocytes and pancreatic acinar cells, suggesting its potential as a therapeutic target for iron overload conditions . More recently, SLC39A14 has been identified as a pro-ferroptotic protein in hepatocytes during liver transplantation, with its inhibition preventing ferroptosis-related damage .

In which tissues and cellular compartments is SLC39A14 predominantly expressed?

SLC39A14 exhibits a distinct tissue distribution pattern that correlates with its biological functions. The highest expression levels are observed in the liver, where SLC39A14 protein is most abundantly localized to hepatocytes . Other organs with significant SLC39A14 expression include the lung, kidney, intestine, blood, heart, vascular tissues, pancreas, muscle, and adipose tissue . This widespread distribution reflects the fundamental importance of zinc and iron transport across multiple physiological systems.

At the subcellular level, SLC39A14 functions primarily as a plasma membrane transporter, consistent with its role in facilitating the uptake of extracellular metal ions. The protein's glycosylation status may influence its membrane localization and function, particularly in the context of varying physiological conditions or disease states . The abundance of SLC39A14 in hepatocytes aligns with the liver's central role in iron metabolism and storage, explaining the protein's critical contribution to hepatic non-transferrin-bound iron uptake.

What types of SLC39A14 antibodies are available for research applications?

Several types of SLC39A14 antibodies are commercially available for research applications, varying in their target epitopes, host species, and detection capabilities. The most common format is rabbit polyclonal antibodies targeting different regions of the SLC39A14 protein. These include antibodies recognizing the internal region (amino acids 240-340), the cytoplasmic domain, and specific amino acid sequences such as 29-58 and 230-280 .

The polyclonal nature of these antibodies offers advantages for detecting native protein in various applications, as they recognize multiple epitopes. Cross-reactivity profiles differ among available products, with some antibodies demonstrating reactivity across multiple species including human, mouse, rat, pig, bat, dog, horse, and monkey samples . Researchers should carefully select antibodies based on their experimental system and target species.

While unconjugated antibodies are most common, conjugated versions with fluorescent labels or enzymes are also available for specialized applications. For instance, APC-conjugated anti-SLC39A14 antibodies offer advantages for flow cytometry or other fluorescence-based detection methods .

For which experimental applications are SLC39A14 antibodies validated?

SLC39A14 antibodies have been validated for multiple experimental applications, enabling comprehensive investigation of this protein across different research contexts. The primary validated applications include:

• Western Blotting (WB): For detecting SLC39A14 protein expression levels in tissue or cell lysates, with optimal antibody concentrations typically ranging from 1-2 μg/mL .

• Immunohistochemistry (IHC-P): For localizing SLC39A14 in paraffin-embedded tissue sections, with recommended starting concentrations of 2.5 μg/mL .

• Immunofluorescence (IF): For visualizing SLC39A14 distribution in cells or tissue sections, typically using concentrations around 20 μg/mL .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of SLC39A14 in solution .

Published validation data includes successful detection of SLC39A14 in human spleen tissue lysates via Western blot and in mouse liver tissue via immunohistochemistry and immunofluorescence . When selecting an antibody for a specific application, researchers should review the validation data provided by manufacturers and consider conducting their own validation experiments, particularly for novel sample types or experimental conditions.

How does SLC39A14 contribute to iron metabolism disorders and hemochromatosis?

SLC39A14 serves as the primary transporter for non-transferrin-bound iron (NTBI) uptake in hepatocytes, making it a critical determinant of hepatic iron loading in hemochromatosis and other iron overload disorders. Studies using Slc39a14-deficient mice crossed with hemochromatosis models (Hfe−/− and Hfe2−/− mice) have provided compelling evidence for this role. Slc39a14 deficiency resulted in a 70% reduction in NTBI uptake by the liver and pancreas, with compensatory increases in uptake by other tissues such as kidney, spleen, and carcass .

Importantly, Slc39a14 deletion in hemochromatotic mice significantly diminished iron accumulation in the liver and prevented pathological iron deposition in hepatocytes and pancreatic acinar cells . This finding has substantial implications for understanding the tissue-specific pathology of hemochromatosis and suggests that SLC39A14 inhibition could represent a targeted therapeutic approach for preventing hepatic and pancreatic damage in iron overload conditions.

The functional capacity of SLC39A14 appears to have a gene dosage effect, as demonstrated by studies with heterozygous animals expressing approximately 50% of wild-type SLC39A14 protein levels. These animals maintained normal hepatic NTBI clearance, indicating that a single functional allele of Slc39a14 is sufficient to sustain normal iron uptake under physiological conditions . This information is valuable for interpreting partial loss-of-function mutations in human populations and their potential impact on iron homeostasis.

What is the relationship between SLC39A14 and ferroptosis in liver pathology?

Recent research has uncovered a critical connection between SLC39A14 and ferroptosis, a form of regulated cell death characterized by iron-dependent lipid peroxidation. Single-cell RNA sequencing analysis of human liver allografts identified SLC39A14 as a pro-ferroptosis factor in hepatocytes . This relationship has significant implications for understanding and addressing liver injury mechanisms, particularly in ischemia-reperfusion injury (IRI) during liver transplantation.

Experimental knockdown of SLC39A14 significantly mitigated hepatic IRI by preventing hepatocyte ferroptosis both in vivo and in vitro . Mechanistically, SLC39A14 inhibition suppresses non-transferrin-bound iron uptake by hepatocytes, thereby reducing cellular iron overload and subsequent ferroptotic cell death. This finding establishes a direct causative link between SLC39A14-mediated iron transport and ferroptosis susceptibility in hepatocytes.

The therapeutic potential of targeting this pathway has been demonstrated using human bone marrow-derived mesenchymal stem cells (hBMSCs), which exert protective effects in hepatic IRI partly by downregulating SLC39A14 expression . Specifically, exosomes derived from hBMSCs deliver miR-16-5p to hepatocytes, which post-transcriptionally suppresses SLC39A14 expression and consequently reduces ferroptosis induced by hepatic IRI . This represents a novel mechanistic insight with potential applications for developing ferroptosis-targeting therapies in liver transplantation and other contexts of hepatic injury.

How can researchers effectively utilize SLC39A14 antibodies to study its role in disease models?

When investigating SLC39A14 in disease models, researchers should implement a comprehensive experimental approach that addresses both protein expression and functional aspects. For protein detection, combining multiple techniques such as Western blotting for quantitative expression analysis, immunohistochemistry for tissue localization, and immunofluorescence for subcellular distribution provides complementary information .

In inflammatory conditions, researchers should consider the regulatory relationship between IL-6 and SLC39A14, as IL-6 modulates SLC39A14 expression in the liver during inflammation and infection . Concurrent measurement of inflammatory markers and SLC39A14 levels can provide insights into this regulatory axis.

For iron metabolism disorders, evaluating SLC39A14 in conjunction with iron parameters is essential. This includes measuring tissue iron content, transferrin saturation, and expression of other iron metabolism genes. The use of radioactive iron (59Fe) uptake assays, as demonstrated in studies with Slc39a14-deficient mice, enables functional assessment of NTBI transport capacity .

In ferroptosis research, SLC39A14 antibodies can be employed alongside ferroptosis markers (e.g., lipid peroxidation indicators, glutathione levels) to correlate SLC39A14 expression with ferroptotic susceptibility . Genetic manipulation of SLC39A14 (knockdown/knockout/overexpression) combined with ferroptosis inducers can establish causative relationships.

For all disease models, researchers should incorporate appropriate controls, including tissue-specific knockout models where available, to distinguish direct SLC39A14 effects from secondary consequences. Additionally, considering the multiple functions of SLC39A14 in transporting both zinc and iron, experimental designs should account for potential confounding effects related to altered homeostasis of either metal.

What experimental challenges exist when investigating SLC39A14 in complex biological systems?

Investigating SLC39A14 in complex biological systems presents several experimental challenges that researchers must navigate. One fundamental challenge is distinguishing between the zinc and iron transport functions of SLC39A14, as alterations in one metal's homeostasis can influence the other. Careful experimental design, including specific metal supplementation or chelation strategies, can help parse these interrelated functions .

Another significant challenge arises from the compensatory mechanisms involving other metal transporters. In Slc39a14-deficient mice, increased NTBI uptake by kidney, spleen, and other tissues suggests compensatory upregulation of alternative transport pathways . Comprehensive analysis of related transporters (other ZIP family members and iron transporters) is advisable to interpret phenotypic changes accurately.

The cell-type specificity of SLC39A14 expression adds another layer of complexity. While SLC39A14 is predominantly expressed in hepatocytes within the liver, investigating its expression and function in non-parenchymal cells requires careful cell isolation procedures and validation of cell-type markers . Single-cell approaches, as employed in recent studies examining SLC39A14 in liver allografts, can overcome this limitation by providing cell-type-resolved information .

In clinical samples, variations in SLC39A14 genetic polymorphisms may influence protein detection by antibodies targeting specific epitopes. Researchers should consider using antibodies recognizing different regions of the protein or complementary detection methods to ensure robust detection across diverse sample populations .

What are optimal protocols for SLC39A14 antibody applications?

Optimizing protocols for SLC39A14 antibody applications requires careful consideration of sample preparation, antibody dilution, and detection methods. For Western blot analysis, published data indicates optimal antibody concentrations of 1-2 μg/mL for detecting SLC39A14 in human spleen tissue lysates . Researchers should use appropriate extraction buffers that effectively solubilize membrane proteins while preserving protein integrity.

For immunohistochemistry applications, a starting concentration of 2.5 μg/mL has been validated for detecting SLC39A14 in mouse liver tissue sections . The fixation method significantly impacts epitope accessibility; therefore, optimization of antigen retrieval conditions is crucial, particularly for formalin-fixed, paraffin-embedded tissues.

Immunofluorescence protocols typically require higher antibody concentrations, with 20 μg/mL reported as effective for visualizing SLC39A14 in mouse liver tissue . Careful selection of secondary antibodies and fluorophores is essential to maximize signal-to-noise ratio and avoid cross-reactivity issues.

For all applications, researchers should validate the specificity of their selected antibody using appropriate positive controls (tissues known to express SLC39A14, such as liver) and negative controls (tissues with low expression or SLC39A14-knockout samples when available) . Cross-validation with multiple antibodies targeting different epitopes can further enhance confidence in experimental results.

Antibody dilution experiments should be performed to determine the optimal concentration for each specific application and sample type. Researchers should also consider potential post-translational modifications of SLC39A14, such as glycosylation, which may affect antibody recognition in different experimental contexts .

How can researchers validate SLC39A14 knockdown or overexpression in experimental models?

Validating SLC39A14 knockdown or overexpression requires a multi-faceted approach combining molecular and functional assessments. At the protein level, Western blot analysis using validated SLC39A14 antibodies provides quantitative measurement of expression changes . Immunoblot images should be quantified with appropriate normalization to loading controls, and statistical analysis should be performed across multiple independent experiments.

RNA-level validation via RT-qPCR provides complementary information, particularly for distinguishing between transcriptional regulation and post-transcriptional mechanisms. When investigating miRNA-mediated regulation, such as miR-16-5p targeting SLC39A14 , researchers should confirm both the miRNA levels and SLC39A14 mRNA levels.

Functional validation is equally important to confirm that expression changes translate to altered transport activity. For SLC39A14, this can be accomplished through metal uptake assays. Radioisotope uptake experiments using 59Fe-labeled ferric citrate provide a direct measure of NTBI transport capacity, as demonstrated in studies with Slc39a14-deficient mice . Zinc uptake assays using fluorescent zinc indicators or radioactive zinc can similarly assess the zinc transport function.

For genetic models (knockout or transgenic), genotyping should be complemented with protein expression analysis across multiple tissues, particularly those with high endogenous SLC39A14 expression like liver and pancreas . Additionally, researchers should evaluate potential compensatory changes in related transporters, as biological systems often upregulate alternative pathways in response to transporter deficiencies.

In disease intervention studies targeting SLC39A14, such as through miRNA delivery , time-course experiments monitoring both the intervention (e.g., miRNA levels) and SLC39A14 expression can provide insights into the kinetics and durability of the effect.

What controls and standards should be included in SLC39A14 antibody-based experiments?

Implementing appropriate controls is essential for generating reliable and interpretable data in SLC39A14 antibody-based experiments. Primary antibody controls should include:

• Positive tissue controls: Liver tissue samples, where SLC39A14 is abundantly expressed, particularly in hepatocytes .

• Negative control samples: Tissues with minimal SLC39A14 expression or, ideally, samples from SLC39A14 knockout models . When knockout samples are unavailable, antibody pre-absorption with the immunizing peptide can serve as an alternative specificity control.

• Concentration-matched isotype controls: Particularly important for immunohistochemistry and immunofluorescence applications to distinguish specific staining from non-specific binding.

• Secondary antibody-only controls: To identify background signal from secondary antibody binding.

For quantitative applications such as Western blotting:

• Loading controls: Appropriate housekeeping proteins that remain stable under the experimental conditions being tested.

• Concentration standards: Recombinant SLC39A14 protein or peptide standards at known concentrations to enable semi-quantitative or quantitative analysis.

• Sample processing controls: Parallel processing of all experimental groups to minimize technical variation.

When investigating SLC39A14 in the context of metal transport:

• Metal loading controls: Samples with confirmed high and low iron or zinc status to demonstrate the antibody's ability to detect SLC39A14 under different metal loading conditions.

• Functional controls: Correlative measurement of transport activity alongside protein expression to establish structure-function relationships.

For disease model studies, particularly those investigating SLC39A14 in inflammation, iron disorders, or ferroptosis, including disease-relevant positive and negative controls enables proper contextualization of findings within the pathophysiological framework.

What are common challenges in detecting SLC39A14 and how can they be overcome?

Researchers frequently encounter several challenges when detecting SLC39A14 protein, largely due to its nature as a multipass membrane protein. One common issue is insufficient protein extraction, as membrane proteins often require specialized lysis buffers containing appropriate detergents to solubilize them effectively. Using buffers containing non-ionic detergents such as Triton X-100 or NP-40, or stronger ionic detergents like SDS for complete denaturation, can improve SLC39A14 extraction from membranes .

Antibody specificity concerns may arise, particularly when detecting endogenous SLC39A14 in complex samples. To address this, researchers should:

• Validate antibodies using positive and negative controls, including SLC39A14 knockout tissues when available .

• Consider using multiple antibodies targeting different epitopes for cross-validation .

• Confirm specificity through peptide competition assays, where pre-incubation of the antibody with the immunizing peptide should abolish specific signal.

Signal detection issues are also common, especially in tissues with lower SLC39A14 expression. These can be addressed by:

• Optimizing antigen retrieval for fixed tissues (for IHC and IF applications).

• Employing signal amplification systems such as tyramide signal amplification for immunohistochemistry or high-sensitivity chemiluminescent substrates for Western blotting.

• Increasing protein loading for Western blot applications while ensuring the linear range of detection is maintained.

Post-translational modifications, particularly glycosylation of SLC39A14, can affect antibody recognition and protein migration patterns on SDS-PAGE. Researchers can address this by:

• Using glycosidase treatments (e.g., PNGase F) to remove N-linked glycans before SDS-PAGE analysis.

• Selecting antibodies that target regions less likely to be affected by post-translational modifications.

For functional studies correlating SLC39A14 expression with metal transport, the overlapping substrate specificity (zinc, iron, and potentially other metals) can complicate interpretation. Researchers should design experiments with appropriate metal chelators or competitors to distinguish between different transport functions.

How can researchers interpret discrepancies in SLC39A14 data across different experimental systems?

Discrepancies in SLC39A14 data across different experimental systems can arise from multiple sources and require careful interpretation. Species differences in SLC39A14 expression, regulation, and function may lead to seemingly contradictory results when comparing human, mouse, and other model systems. While SLC39A14 is conserved across species, variations in its tissue distribution, regulatory elements, and functional importance may exist . Researchers should acknowledge these potential differences and avoid direct extrapolation without appropriate validation.

Methodological variations in antibody selection, application protocols, and detection systems can significantly impact results. When comparing studies, researchers should consider:

• Antibody characteristics: Different epitope targets may yield varying results, especially if the protein's conformation or post-translational modifications affect epitope accessibility .

• Protocol differences: Variations in sample preparation, antibody concentration, incubation conditions, and detection methods can all influence sensitivity and specificity.

• Quantification approaches: Different normalization strategies and quantification methods may produce apparently discrepant results.

Biological context significantly influences SLC39A14 expression and function. Factors to consider when interpreting discrepancies include:

To resolve discrepancies, researchers are encouraged to:

• Directly compare experimental conditions by replicating key experiments using standardized protocols.

• Employ complementary methodologies to corroborate findings.

• Consider contextual factors that might explain seemingly contradictory results.

• Utilize genetic models (e.g., Slc39a14 knockout mice) to establish definitive phenotypes and functions .

What emerging research areas involve SLC39A14 antibodies?

Several promising research directions are emerging at the intersection of SLC39A14 biology and disease mechanisms, where SLC39A14 antibodies will play crucial investigative roles. The recently established connection between SLC39A14 and ferroptosis in liver pathology opens significant avenues for exploration in the context of other ferroptosis-sensitive disorders . Researchers can apply SLC39A14 antibodies to investigate expression patterns and correlations with ferroptotic markers in neurodegenerative diseases, cardiac ischemia-reperfusion injury, and cancer contexts where ferroptosis is implicated.

The therapeutic potential of SLC39A14 modulation in hemochromatosis and iron overload disorders represents another frontier . As pharmacological inhibitors of SLC39A14 are developed, antibodies will be essential tools for validating target engagement, measuring expression changes, and correlating protein levels with functional outcomes in preclinical models and potentially clinical samples.

The regulatory relationship between inflammation and SLC39A14 expression warrants deeper investigation, particularly in chronic inflammatory conditions . SLC39A14 antibodies will enable researchers to track expression changes during disease progression and in response to anti-inflammatory interventions, potentially revealing new therapeutic targets.

The role of exosomal miRNA regulation of SLC39A14, as demonstrated with miR-16-5p delivery by mesenchymal stem cell-derived exosomes , opens exciting possibilities for targeted gene regulation approaches. Antibodies will be critical for validating the efficacy of such interventions at the protein level across different experimental models and potential therapeutic applications.

Single-cell approaches combined with SLC39A14 immunostaining could reveal previously unrecognized cell-type-specific expression patterns and functions beyond the established role in hepatocytes . This may uncover specialized roles in diverse physiological and pathological contexts.

Finally, the potential involvement of SLC39A14 genetic variants in disease susceptibility represents an emerging area where antibodies that can distinguish between variant protein forms would be valuable for understanding structure-function relationships and potential personalized medicine approaches.

How might SLC39A14 research translate to clinical applications?

The translation of SLC39A14 research to clinical applications spans diagnostic, prognostic, and therapeutic domains. In diagnostics, SLC39A14 antibodies could be developed for immunohistochemical assessment of biopsy samples from patients with suspected metal metabolism disorders or liver diseases. Expression patterns might serve as biomarkers for disease classification or prognostication, particularly in conditions where iron dysregulation contributes to pathology .

The established role of SLC39A14 in hepatic iron accumulation suggests significant therapeutic potential for inhibiting this transporter in hemochromatosis and related iron overload disorders . Small molecule inhibitors, antibody-based approaches, or RNA therapeutics targeting SLC39A14 could potentially mitigate organ damage by preventing excessive iron uptake by hepatocytes and pancreatic acinar cells. Preclinical validation of such approaches would rely heavily on SLC39A14 antibodies to confirm target engagement and expression modulation.

The recently discovered connection between SLC39A14 and ferroptosis in liver ischemia-reperfusion injury reveals a promising avenue for liver transplantation medicine . Therapies targeting SLC39A14 expression or function could potentially reduce organ damage during transplantation procedures. The demonstrated efficacy of mesenchymal stem cell-derived exosomes containing miR-16-5p in downregulating SLC39A14 and preventing ferroptosis provides a foundation for developing exosome-based or other RNA therapeutic approaches .

For inflammatory conditions where hypozincemia contributes to pathology, understanding the regulatory relationship between IL-6 and SLC39A14 could inform interventions aimed at normalizing zinc homeostasis . SLC39A14 antibodies would be essential tools for monitoring the efficacy of such interventions in modulating protein expression.

As personalized medicine advances, genetic variations in SLC39A14 might inform individual susceptibility to metal-related disorders or response to specific therapies. Antibodies capable of distinguishing variant forms or detecting altered expression patterns could contribute to patient stratification and treatment selection.

The development of clinically applicable SLC39A14-targeted therapies would necessitate comprehensive safety evaluation, considering the protein's physiological roles in metal homeostasis across multiple tissues. Antibody-based detection methods would play a central role in assessing both on-target effects and potential off-target consequences during preclinical and clinical development.